IceCure Medical Sees Q4 Revenue at $1.90M, EPS of -$0.05
IceCure Medical forecasts Q4 2025 revenue of $1.90 million with EPS of -$0.05 and full year 2025 revenue of $3.87 million with EPS of -$0.22. The average one-year price target of $3.13 implies 353% upside, while a GF Value estimate of $0.54 suggests 22% downside.
1. Upcoming Q4 2025 Earnings Estimates
IceCure Medical will report Q4 2025 results on March 17, with forecasts calling for $1.90 million in revenue and a $0.05 per-share loss. Full year 2025 revenue is expected at $3.87 million with a loss of $0.22 per share.
2. Recent Estimate Trends and Past Performance
Over the past 90 days, full-year 2025 revenue estimates rose from $3.67 million to $3.87 million, while 2026 revenue forecasts remain unchanged at $5.00 million. In Q3 2025, IceCure generated $0.85 million, beating revenue expectations by 19% but missing EPS forecasts with a $0.06 per-share loss.
3. Analyst Price Targets and Brokerage Recommendations
Two analysts set an average one-year price target of $3.13, implying a 353% increase from the current price, while the GF Value estimate of $0.54 points to a 22% decline. The consensus brokerage rating stands at 2.0, signaling an Outperform stance.